



Press release, 2025-04-28  
Malmö, Sweden

## **aXivite fuels record demand as Triquetra Health's GLP-Activate™ climbs to top-seller status**

[aXichem AB](#) (publ), (aXichem), the developer of innovative natural analogue feed additives and food supplement ingredients, today reports that GLP-Activate™, launched in April 2024 by Triquetra Health, is now one of the retailer's leading products and a key growth driver for aXichem's nutraceutical ingredient aXivite.

"GLP-Activate has exceeded every sales benchmark we set. Consumers are actively seeking science-backed solutions that mimic GLP-1 benefits without the side-effects reported for semaglutide injectables. aXivite allows them to preserve lean mass while reducing fat, delivering real metabolic advantages in a convenient capsule.", said Elias Chiatas, CEO of SEE Nutrition, aXichem's commercial agent in the United States.

"SEE Nutrition anticipates that this weight-loss category will contribute approximately an additional 7 M SEK in aXivite sales for delivery over the next 12 months, supporting aXichem's sales for the 2025 financial year.", said Lucas Altepost, VP Sales and Marketing at aXichem.

### **Strong category tail-winds**

U.S. retailers identify "nutritional support for GLP-1 users" and natural GLP-1 boosters as a leading 2025 wellness trend. The global GLP-1 analogue drugs market is projected to reach USD 47 billion in 2025, with complementary categories benefiting from halo demand.

### **Scientific validation of aXivite**

Clinical research shows that phenylcapsaicin (aXivite) significantly reduces body-fat while preserving lean mass and supports gut-barrier integrity. Additional studies demonstrate improved aerobic capacity and metabolic efficiency.

### **About GLP-Activate™**

GLP-Activate combines aXivite phenylcapsaicin with botanicals designed to stimulate endogenous GLP-1 release, helping users manage appetite and cravings while sustaining metabolic health. The once-daily capsule offers a drug-free alternative for consumers hesitant about prescription injectables amid growing media coverage of side-effects and supply shortages.

The information was submitted, through the care of the contact person below, for publication on 28 April 2025, at 9:00 AM CET.

**Company contact:**

Torsten Helsing, CEO, aXichem AB

Phone: +46 706 863 355 Email: [torsten.helsing@axichem.com](mailto:torsten.helsing@axichem.com)

**About aXichem**

aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB.

More about aXichem at [www.axichem.com](http://www.axichem.com).